What Is a Cardiac PET Scan and How Does It Work?

Introduction

Cardiac PET imaging represents the most accurate noninvasive method for evaluating blood flow to the heart muscle. Unlike tests that show only whether blood flow appears normal or abnormal, PET quantifies exactly how much blood reaches each region of the heart. This precision matters because it detects problems that other imaging methods miss and provides prognostic information that directly informs treatment decisions.

The technology works by tracking radioactive tracers as they flow through the coronary circulation. A specialized camera detects the radiation emitted by these tracers, creating detailed maps of myocardial perfusion at rest and during stress. The resulting measurements of myocardial blood flow and coronary flow reserve have become increasingly important for identifying patients at risk for cardiac events, even when traditional stress tests appear normal.

This article explains the fundamentals of cardiac PET imaging, from basic principles to patient experience. Understanding what the test measures and how it works provides the foundation for evaluating whether it might benefit your care. Subsequent articles address technology and equipment considerations, how to interpret results, and how PET compares to alternatives.

What is a cardiac PET scan and how does it differ from other heart imaging tests?

A cardiac PET scan is a nuclear medicine imaging study that measures blood flow to the heart muscle using radioactive tracers and specialized detectors. The patient receives an intravenous injection of a tracer that distributes throughout the myocardium in proportion to blood flow. A ring-shaped camera surrounding the patient detects the radiation emitted when the tracer decays, creating three-dimensional images of perfusion throughout the heart.

The key distinction from other cardiac imaging lies in PET’s ability to quantify blood flow in absolute terms. Standard stress tests with SPECT imaging show relative perfusion differences between heart regions but cannot measure actual flow rates. CT angiography reveals anatomic blockages but not their physiologic significance. PET provides both qualitative perfusion images and quantitative measurements of myocardial blood flow that predict outcomes independent of anatomic findings (Schindler et al., 2010).

This quantitative capability enables detection of diffuse coronary artery disease and microvascular dysfunction that other tests miss entirely. When disease affects all three major coronary arteries equally, relative perfusion imaging may appear normal because no region looks worse than another. PET’s absolute flow measurements reveal the global reduction in coronary reserve that indicates significant disease burden.

What does PET stand for and what basic principle allows it to create images of the heart?

PET stands for positron emission tomography. The technique relies on tracers labeled with radioactive isotopes that decay by emitting positrons. When a positron encounters an electron in surrounding tissue, both particles annihilate and produce two high-energy photons traveling in exactly opposite directions. Detectors arranged in a ring around the patient register these paired photons, and the scanner uses their simultaneous detection to localize where the annihilation event occurred.

This coincidence detection mechanism provides superior spatial resolution and image quality compared to single-photon imaging techniques like SPECT. The physics of positron annihilation allow precise localization of tracer activity within the body. Modern PET scanners achieve spatial resolution of 4-6 millimeters, sufficient to distinguish perfusion differences between the inner and outer layers of the heart wall.

The mathematical reconstruction of PET images also enables absolute quantification of tracer concentration in tissue. By measuring both the tracer entering the heart through the blood and the tracer taken up by the myocardium, PET can calculate actual blood flow rates in milliliters per minute per gram of tissue. This quantitative capability distinguishes PET from all other noninvasive perfusion imaging methods (Chen et al., 2019).

What are radioactive tracers and how do they reveal information about heart function?

Radioactive tracers are molecules labeled with unstable isotopes that emit detectable radiation as they decay. For cardiac perfusion imaging, the ideal tracer enters heart muscle cells in proportion to blood flow, remains trapped long enough for imaging, and emits radiation that the scanner can detect efficiently. The distribution pattern of tracer throughout the myocardium creates a map of relative and absolute blood flow.

The tracers used in cardiac PET have short half-lives, meaning they decay and lose their radioactivity quickly. Rubidium-82 has a half-life of only 75 seconds. Nitrogen-13 ammonia lasts about 10 minutes. These short half-lives allow rapid sequential imaging at rest and during stress while minimizing total radiation exposure to the patient. The brief decay also means tracers must be produced on-site or nearby.

Different tracers have different extraction characteristics that affect how accurately they reflect true myocardial blood flow. At very high flow rates, some tracers cannot be extracted by heart cells as quickly as blood delivers them, causing the measured uptake to underestimate true flow. Understanding these tracer kinetics is essential for accurate flow quantification and interpretation of results (Valenta and Schindler, 2024).

What tracers are used in cardiac PET and what does each one measure?

The three main tracers for cardiac PET perfusion imaging are rubidium-82, nitrogen-13 ammonia, and the recently approved fluorine-18 flurpiridaz. Each measures myocardial blood flow but differs in production requirements, imaging characteristics, and quantitative accuracy. Rubidium-82 dominates clinical practice because it comes from a generator that can be installed at imaging facilities without an on-site cyclotron.

Rubidium-82 is produced by a strontium-82/rubidium-82 generator that sits in the imaging suite and continuously produces fresh tracer. The generator requires replacement approximately monthly. Nitrogen-13 ammonia requires an on-site cyclotron for production, limiting its availability to academic medical centers. However, ammonia offers superior image quality and more accurate flow quantification at high flow rates (Higuchi et al., 2025).

Fluorine-18 flurpiridaz received FDA approval in 2024 and represents a significant advance. Its two-hour half-life allows production at regional cyclotron facilities and distribution to imaging centers without cyclotrons. Early studies suggest it provides excellent image quality and accurate flow quantification across a wide range of flow rates. Wider clinical adoption is expected as supply chains develop.

What is the difference between a perfusion PET scan and a viability PET scan?

Perfusion PET evaluates blood flow to the heart muscle, while viability PET assesses whether heart muscle is alive and potentially recoverable. These represent different clinical questions requiring different tracers and protocols. Perfusion imaging uses flow tracers like rubidium-82 or ammonia to detect ischemia and quantify coronary flow reserve. Viability imaging typically uses fluorine-18 fluorodeoxyglucose (FDG), a glucose analog that accumulates in metabolically active tissue.

Viability assessment becomes relevant when a patient has reduced heart function and doctors must decide whether revascularization might help. Heart muscle that receives inadequate blood flow may stop contracting but remain alive in a state called hibernation. If viable, this muscle can recover function after blood flow is restored. FDG-PET identifies hibernating myocardium by detecting ongoing glucose metabolism in regions with reduced blood flow (Guduguntla and Weinberg, 2025).

The combined information from perfusion and metabolism imaging creates a classification system. Matched reductions in flow and metabolism suggest scar. Reduced flow with preserved metabolism indicates hibernating but viable muscle. Normal flow with normal metabolism represents healthy tissue. This classification guides decisions about whether to pursue revascularization versus medical therapy alone.

What is myocardial blood flow and why is it important?

Myocardial blood flow (MBF) refers to the volume of blood delivered to the heart muscle per unit time, typically expressed as milliliters per minute per gram of tissue. Normal resting MBF is approximately 0.6-1.0 mL/min/g. During maximal stress, healthy coronary arteries can increase flow three to four times above resting levels. The ability to measure these values directly distinguishes PET from other noninvasive imaging techniques.

Absolute MBF measurements matter because they detect disease patterns that relative imaging misses. When all three coronary arteries have similar degrees of obstruction, the heart may show uniform tracer uptake that appears normal on relative perfusion images. Quantitative PET reveals the globally reduced flow that indicates significant three-vessel coronary artery disease requiring aggressive treatment (Schindler et al., 2010).

Stress MBF also provides independent prognostic information. Patients with reduced stress flow face higher rates of cardiac events regardless of what anatomic imaging shows about their coronary arteries. This functional assessment helps identify which patients need more intensive therapy and which can be managed conservatively.

What is coronary flow reserve and what does it tell you about your heart?

Coronary flow reserve (CFR) is the ratio of blood flow during maximal stress to blood flow at rest. A healthy coronary circulation can increase flow at least threefold during exercise or pharmacologic stress, yielding a CFR of 3.0 or higher. Values below 2.0 are generally considered abnormal and indicate impaired coronary vasodilator capacity. CFR integrates information about both large coronary arteries and the microvascular circulation.

The clinical value of CFR lies in its ability to capture the total hemodynamic impact of coronary disease. A 50% stenosis in one artery might reduce flow in that territory, but the overall CFR also reflects contributions from microvascular dysfunction, diffuse atherosclerosis, and other factors affecting coronary blood flow. Studies show that reduced CFR predicts cardiovascular events even when traditional risk factors and imaging findings appear reassuring (Nayfeh et al., 2023).

CFR also identifies coronary microvascular dysfunction, a condition where the small blood vessels of the heart cannot dilate properly despite open large arteries. Patients with microvascular dysfunction experience angina and have increased cardiovascular risk, but they typically have normal stress tests and coronary angiograms. PET’s ability to quantify CFR provides objective evidence of this often-overlooked condition.

What happens during a cardiac PET scan from arrival to completion?

Patients arrive at the imaging facility after fasting and avoiding caffeine for at least 12-24 hours. A technologist places an intravenous line for tracer injection and applies ECG electrodes for cardiac monitoring. The patient lies on a narrow table that slides into the PET scanner, a large donut-shaped machine that surrounds the chest. The opening is wide enough that most patients do not feel claustrophobic.

The imaging protocol begins with a low-dose CT scan for attenuation correction, which adjusts for how the body absorbs radiation before it reaches the detectors. The technologist then injects the perfusion tracer, and the scanner acquires resting images over several minutes. After resting imaging, the patient receives a pharmacologic stress agent to dilate the coronary arteries and increase blood flow. A second tracer dose is injected at peak stress, and stress images are acquired.

The entire procedure typically takes 45-90 minutes depending on the specific protocol and tracer used. Patients remain on the scanner table throughout but can communicate with the technologist via intercom. After imaging concludes, the intravenous line is removed, and patients can typically resume normal activities immediately. Results require interpretation by a nuclear cardiologist and are usually available within a few days.

How long does a cardiac PET scan take?

Total appointment time for a cardiac PET scan ranges from 60 to 120 minutes. The actual imaging acquisition takes approximately 30-45 minutes for most protocols. Additional time is required for patient preparation, IV placement, positioning, and monitoring during the stress portion of the examination. Some facilities schedule 90-minute appointments to allow adequate time without rushing.

The specific timing depends on which tracer is used. Rubidium-82’s 75-second half-life allows rapid sequential imaging, with rest and stress acquisitions completed in under an hour. Nitrogen-13 ammonia’s 10-minute half-life requires a waiting period between rest and stress imaging for the first tracer dose to decay, extending total procedure time. The newer F-18 flurpiridaz protocols are still being optimized for clinical efficiency (Higuchi et al., 2025).

Patients should plan to spend approximately two hours at the facility when accounting for check-in, preparation, and post-procedure observation. Unlike exercise stress tests, most cardiac PET studies use pharmacologic stress, so patients do not need to arrive prepared for vigorous physical exertion. The time investment is modest compared to the clinical information obtained.

What stress agents are used during cardiac PET and how do they work?

Pharmacologic stress agents for cardiac PET dilate the coronary arteries to simulate the increased blood flow that occurs during exercise. The most commonly used agents are adenosine, dipyridamole, and regadenoson. All three work through adenosine receptors in the coronary vessels, causing smooth muscle relaxation and vasodilation. The choice among them depends on institutional preference, patient characteristics, and contraindications.

Adenosine requires continuous intravenous infusion over 4-6 minutes and causes vasodilation throughout the body. Side effects include flushing, chest discomfort, and shortness of breath, which resolve quickly when the infusion stops. Dipyridamole works by blocking adenosine breakdown, prolonging its vasodilatory effect. Regadenoson is given as a single bolus injection and selectively targets coronary adenosine receptors, potentially causing fewer systemic side effects.

Patients with asthma or significant reactive airway disease may not be able to receive adenosine-based agents safely due to risk of bronchospasm. Dobutamine serves as an alternative in these patients, increasing heart rate and contractility to simulate exercise stress (Bacharach et al., 2003). Exercise stress is occasionally used with PET but is technically challenging due to the need for tracer injection at peak exercise while the patient lies on the scanner table.

What does the rest portion of the scan show versus the stress portion?

Resting images establish baseline myocardial perfusion when the heart is doing minimal work. In normal patients, tracer distributes uniformly throughout the left ventricle at rest. Regions with reduced resting perfusion indicate either scar from prior heart attack or severely reduced blood flow from tight coronary stenoses. Resting myocardial blood flow is typically similar across patients regardless of coronary artery disease severity.

Stress imaging reveals perfusion deficits that appear only when the heart demands more blood flow. Normal coronary arteries dilate and increase flow three to four-fold during stress. Diseased arteries cannot augment flow as effectively, causing the territory they supply to appear relatively underperfused compared to normal regions. This stress-induced perfusion heterogeneity identifies the presence and location of significant coronary disease (Chen et al., 2019).

Comparing rest and stress images characterizes the nature of perfusion abnormalities. A defect present only during stress indicates inducible ischemia from flow-limiting coronary disease. A defect present at both rest and stress suggests scar or hibernating myocardium. The extent, severity, and reversibility of perfusion abnormalities all contribute to risk assessment and treatment planning.

How should you prepare for a cardiac PET scan?

Preparation for cardiac PET requires avoiding caffeine for at least 12-24 hours before the test. Caffeine blocks adenosine receptors, which can prevent the stress agent from working properly. This restriction includes coffee, tea, chocolate, many soft drinks, and some medications. Patients should check ingredient labels carefully and ask their physician if they are uncertain about specific products.

Most protocols require fasting for at least 4-6 hours before imaging to optimize tracer uptake and image quality. Water is generally permitted. Patients should bring a list of current medications to their appointment. Some medications may need to be held before the test, particularly beta-blockers and calcium channel blockers that could affect heart rate response to stress. The ordering physician typically provides specific instructions about medication management.

Comfortable, loose-fitting clothing without metal snaps or zippers works best for the procedure. Patients should inform the imaging staff about any allergies, prior reactions to contrast agents or radioactive tracers, and current health conditions including pregnancy. The preparation guidelines from major nuclear cardiology societies provide detailed recommendations that facilities adapt to their specific protocols (Bacharach et al., 2003).

What does the scanner look like and what will you experience while inside it?

The PET scanner resembles a large, donut-shaped machine with a central opening typically 70-80 centimeters in diameter. Patients lie on a narrow, padded table that slides into this opening. Unlike MRI machines, PET scanners do not require a long, enclosed tunnel, and most patients do not experience claustrophobia. The room is typically cool to optimize detector performance.

During imaging, patients hear humming from the scanner and occasional mechanical sounds as the table moves to position different parts of the chest within the imaging field. The scanner itself is quiet compared to MRI machines. Patients must remain still during image acquisition, typically for periods of 2-10 minutes at a time. Technologists communicate through an intercom and can see patients through a window.

The stress portion of the examination produces noticeable sensations. Adenosine and regadenoson commonly cause flushing, warmth, chest tightness, and shortness of breath. These effects feel alarming to some patients but are expected and resolve within minutes after the stress agent is stopped. Informing patients what to expect reduces anxiety and improves the examination experience (Schelbert et al., 2003).

Is a cardiac PET scan painful or uncomfortable?

The cardiac PET scan itself causes no pain. IV placement involves brief discomfort similar to a routine blood draw. The scanner makes no contact with the patient’s body. Lying still on a firm table for 30-60 minutes may cause back discomfort in some patients, particularly those with pre-existing musculoskeletal issues. Pillows or positioning aids can help.

The pharmacologic stress portion produces transient discomfort that varies by patient and agent used. Common symptoms include facial flushing, chest heaviness, shortness of breath, headache, and nausea. Regadenoson tends to cause fewer symptoms than adenosine in many patients. These sensations typically last only 2-5 minutes and resolve quickly once the stress agent clears the system or is reversed with aminophylline.

Patients should communicate any concerning symptoms to the technologist immediately. Severe reactions are rare but staff are trained to manage them. The discomfort of pharmacologic stress, while unpleasant, is brief and generally well-tolerated. Most patients describe the experience as manageable and would repeat the test if medically indicated.

What are the immediate risks or side effects during the procedure?

Serious adverse events during cardiac PET are rare. The stress agents can cause arrhythmias, severe hypotension, or bronchospasm in susceptible individuals. Facilities monitor patients throughout the procedure with continuous ECG and periodic blood pressure measurements. Staff have resuscitation equipment and reversal agents immediately available.

Common transient effects from pharmacologic stress include headache, flushing, chest discomfort, and gastrointestinal symptoms. These occur in a substantial proportion of patients but resolve spontaneously within minutes. Aminophylline can be given to reverse adenosine-related symptoms more quickly if needed. Rarely, patients experience more prolonged symptoms requiring additional observation.

The radioactive tracers used in cardiac PET carry no immediate risks. The injected doses are too small to cause any physiologic effects. The radiation exposure is a long-term consideration rather than an immediate risk. Safety monitoring data from large registries confirm that cardiac PET is a safe procedure when performed according to established guidelines (Pelletier-Galarneau et al., 2024).

How much radiation exposure does a cardiac PET scan involve and how does this compare to other imaging tests?

Radiation exposure from cardiac PET depends on the tracer and protocol used. Rubidium-82 studies deliver approximately 2-5 millisieverts (mSv) of effective dose. Nitrogen-13 ammonia protocols result in similar or slightly lower exposure. Adding a CT scan for attenuation correction increases total exposure by 0.5-2 mSv depending on CT technique. Total effective doses for most cardiac PET studies range from 2-7 mSv.

For context, this exposure compares favorably to other cardiac imaging procedures. SPECT myocardial perfusion imaging typically delivers 9-12 mSv. Diagnostic coronary CT angiography ranges from 2-10 mSv depending on technique and scanner generation. Diagnostic cardiac catheterization delivers approximately 5-10 mSv. Annual background radiation exposure in the United States averages about 3 mSv.

The low radiation dose of PET relative to its diagnostic value represents one of its advantages over SPECT for patients requiring perfusion imaging (Alam et al., 2023). For serial monitoring of disease progression, cumulative radiation exposure becomes a consideration. Physicians weigh the clinical benefit of repeat imaging against long-term radiation risk when determining appropriate follow-up intervals.

Conclusion

Cardiac PET imaging provides uniquely quantitative information about myocardial blood flow and coronary flow reserve. The technology uses radioactive tracers and coincidence detection to create precise maps of perfusion throughout the heart. These measurements detect disease that other tests miss and predict cardiovascular risk with accuracy unmatched by alternative imaging methods.

Understanding the fundamentals of cardiac PET helps patients engage meaningfully in discussions about whether this test might benefit their care. The procedure is safe, well-tolerated, and provides information that directly informs treatment decisions. For patients with known or suspected coronary artery disease, and particularly those with risk factors for microvascular dysfunction, cardiac PET offers diagnostic capabilities that can change management.

The next articles in this series examine scanner technology and technical precision, how to interpret PET results, and how cardiac PET compares to alternative imaging approaches. For patients considering whether to pursue cardiac PET, the self-advocacy and navigation article provides practical guidance on accessing this technology.